Fludarabine and Total-Body Irradiation Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib - Related Studies

Fludarabine and Total-Body Irradiation Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

This study is currently recruiting participants.

Study NCT00036738. Last updated on October 24, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia

2	Additional conditions recognized in this trial
		Leukemia, Lymphoid
		Leukemia, Myelogenous, Chronic, BCR-ABL Positive
		Leukemia, Myeloid
		Precursor Cell Lymphoblastic Leukemia-Lymphoma

3	More general conditions related to this trial
		Bone Marrow Diseases
		Hematologic Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Myeloproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		cyclosporine
		dasatinib
		fludarabine phosphate
		imatinib mesylate
		mycophenolate mofetil
		nilotinib
		therapeutic allogeneic lymphocytes
		radiation therapy

5	Additional drug interventions recognized in this trial
		Cyclosporins
		Fludarabine
		Fludarabine monophosphate
		Imatinib

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antifungal Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antirheumatic Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Fred Hutchinson Cancer Research Center
		National Cancer Institute (NCI)